Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions
Atrium spun out of Avidity Biosciences, which Novartis acquired in a $12 billion deal. The Atrium pipeline is led by ...
Atrium spun out of Avidity Biosciences, which Novartis acquired in a $12 billion deal. The Atrium pipeline is led by ...
The Trump Administration on Monday launched detailed steerage for approving the primary bespoke medicines crafted to deal with sufferers’ particular person ...
Disc Medication’s effort to introduce a brand new remedy for a uncommon blood dysfunction with few remedy choices has been ...
For greater than a decade, PTC Therapeutics has been going backwards and forwards with the FDA to discover a path ...
The trigger traced again to a extreme elbow harm in his youth, one which steadily reshaped each bone and every ...
A systematic review of more than 200 studies published in BMC Infectious Diseases on human viruses over more than a ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
BioMarin said Friday it would purchase Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...
The 62 children who were found to have the rare "Bubble Boy disease" as babies and toddlers between 2012 and ...
The FDA has halted clinical testing of an Intellia Therapeutics gene-editing therapy following a report that a patient in a ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.